Form 4 for ROIV Roivant Sciences Ltd.
Accepted 2025-12-31 00:00:00 ET · period of report 2025-12-29 · accession 0001140361-25-047122 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-12-31 | 2025-12-29+ | ROIV | Sukhatme Mayukh | Pres, CIO, Dir | S - Sale+OE | $21.72 | -1.33M | 20.27M | -6% | -$28.90M |
| DM | 2025-12-31 | 2025-12-29+ | ROIV | Sukhatme Mayukh | Pres, CIO, Dir | J - Other | $21.72 | -1.87M | 18.84M | -9% | -$40.55M |
| DM | 2025-12-31 | 2025-12-29+ | ROIV | Sukhatme Mayukh | Pres, CIO, Dir | M - OptEx | $12.68 | +3.20M | 19.58M | +20% | +$40.55M |
| DM | 2025-12-31 | 2025-12-29+ | ROIV | Sukhatme Mayukh | Pres, CIO, Dir | M - OptEx | $0.00 | -3.20M | 555.8K | -85% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2025-12-29 | S | D | 311,873 | $21.74 | 19,273,032 | D | — | — | (F2) These Common Shares were sold in multiple transactions at prices ranging from $21.70 to $21.90, inclusive. (F1) All options exercised by the reporting person would have expired in March 2026 if not exercised. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. |
| 2 | Common | Common Shares | 2025-12-31 | J | D | 1,430,882 | $21.71 | 18,836,547 | D | — | — | (F4) Represents the "net settlement" by the Issuer of stock options previously granted to the reporting person in order to satisfy the exercise price applicable to such stock options. (F1) All options exercised by the reporting person would have expired in March 2026 if not exercised. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. |
| 3 | Common | Common Shares | 2025-12-31 | S | D | 1,018,995 | $21.71 | 20,267,429 | D | — | — | (F3) These Common Shares were sold in multiple transactions at prices ranging from $21.70 to $21.74, inclusive. (F1) All options exercised by the reporting person would have expired in March 2026 if not exercised. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. |
| 4 | Common | Common Shares | 2025-12-31 | M | A | 2,449,877 | $12.68 | 21,286,424 | D | — | — | |
| 5 | Common | Common Shares | 2025-12-29 | M | A | 748,358 | $12.68 | 19,584,905 | D | — | — | |
| 6 | Common | Common Shares | 2025-12-29 | J | D | 436,485 | $21.74 | 18,836,547 | D | — | — | (F4) Represents the "net settlement" by the Issuer of stock options previously granted to the reporting person in order to satisfy the exercise price applicable to such stock options. (F1) All options exercised by the reporting person would have expired in March 2026 if not exercised. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. |
| 7 | Derivative | Stock Option (Right to Buy) | 2025-12-31 | M | D | 2,449,877 | $0.00 | 95,718 | D | $12.68 · — to 2026-03-31 | 2,449,877 Common Shares | (F5) Award of stock options to purchase Common Shares that is fully vested. |
| 8 | Derivative | Stock Option (Right to Buy) | 2025-12-29 | M | D | 748,358 | $0.00 | 555,840 | D | $12.68 · — to 2026-03-31 | 748,358 Common Shares | (F5) Award of stock options to purchase Common Shares that is fully vested. |